Searchable abstracts of presentations at key conferences in endocrinology

ea0063s23.3 | PCOS: can we personalise treatment? | ECE2019

Treatment options in cardiometabolic pcos phenotype

Jensterle Mojca

Background: Cardiometabolic polycystic ovary syndrome (PCOS) phenotype is predominantly characterized by obesity. It is clearly associated with impaired metabolic and reproductive health, whereas implications on cardiac health are mostly limited with the exploration of cardiovascular risk factors without actual cardiovascular endpoints. There is a relative lack of systematic prospective studies investigating long-term effects of different treatment options that include phenoty...

ea0090p133 | Pituitary and Neuroendocrinology | ECE2023

Rare adverse event of treatment with somapacitan after switch from somatotropine

Rakusa Matej , Janez Andrej , Jensterle Mojca

Introduction: Somapacitan is 23.3-kDa human GH derivate linked to small noncovalent albumin binding moiety that facilitates reversible endogenous albumin binding to delay somapacitan elimination. The longer half-life and improved pharmacodynamics allow injections once per week. Some patients find a daily regimen with established treatment difficult, especially because treatment may be lifelong or at least for several years. Poor adherence with medication can lead to poorer cli...

ea0049gp136 | Female Reproduction | ECE2017

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin improved beta cell function and prevented a conversion rate to MTG and DM2 in metformin intolerant PCOS with high metabolic risk

Janez Andrej , Ferjan Simona , Jensterle Mojca

Objective: Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.Design and m...

ea0041ep673 | Female Reproduction | ECE2016

Improvement of beta-cell function with DPP-4 inhibitor alogliptin vs alogliptin in combination with pioglitazone as a potential treatment target in metformin treated PCOS with persistent high metabolic risk: randomized pilot study

Jensterle Mojca , Goricar Katja , Janez Andrej

Introduction: High conversion rates to impaired glucose tolerance (IGT) and diabetes in PCOS indicate that current treatment strategy with lifestyle modification and metformin is insufficient. Preservation of β-cell function remains unaddressed although it is declined by 80% long before IGT is identified. Alogliptin is selective dipeptidyl peptidase-4 inhibitor improving insulin sensitivity (IS) and β-cell function. Pioglitazone predominantly improv...

ea0070aep223 | Bone and Calcium | ECE2020

Trabecular bone score assessment in heart transplant recipients stratified by time after transplantation

Rakusa Matej , Janez Andrej , Jensterle Mojca

Objective: Bone strength post heart transplant (HT) is affected by many factors including glucocorticoids, calcineurin inhibitors, hypogonadism, vitamin D deficiency, secondary hyperparathyroidism and cachexia. Trabecular bone score (TBS), novel texture index derived from lumbar spinal DXA improves fracture risk assessment in several different high-risk populations, whereas it remains largely understudied in HT recipients. We aimed to evaluate factors that affect TBS after HT....

ea0070aep760 | Pituitary and Neuroendocrinology | ECE2020

Associations of endocrine and metabolic complications of childhood- and adult-onset craniopharingeoma with the histological subtype

Jazbinsek Soncka , Jensterle Mojca , Kotnik Primoz

Objective: Studies comparing endocrine and metabolic outcomes of childhood- and adult-onset craniopharyngioma (CP) are generally based on the age-of-disease onset only. The aim of this study was to analyze the role of histological tumor subtype (adamantinomatous (aCP) or papillary (pCP)) on the development of long-term endocrine and metabolic CP comorbidities.Methods: 47 patients with CP treated from 1979 onwards (19 patients with childhood-onset disease...

ea0056gp129 | Female Reproduction | ECE2018

Impaired GLP-1 response predicts prediabetes in obese PCOS with adverse metabolic phenotype independent of BMI

Jensterle Mojca , Ferjan Simona , Janez Andrej

Objective: Impaired glucose homeostasis in PCOS is closely linked to obesity, age and disease phenotype. The potential separate role of reduced GLP-1 response in the development of prediabetes in this population is unclear.Aim: To compare the GLP-1 response after OGTT in a cohort of obese PCOS with normal glucose tolerance (NGT) and prediabetes.Design/participants/methods: Case control study recruited 26 obese Caucasian women with ...

ea0081p163 | Pituitary and Neuroendocrinology | ECE2022

Clinical applicability of using SAGIT instrument and AcroQol in the management of patients with acromegaly

Herman Rok , Goricar Katja , Janez Andrej , Jensterle Mojca

Objective: We aimed to evaluate the ability of SAGIT Instrument and AcroQoL questionnaire to discriminate acromegaly control status and to correlate SAGIT scores to AcroQoL results in a cohort of the national referral centre.Methods: Cross-sectional study included 72 patients followed between 2000 and 2020. We retrospectively determined SAGIT score at the diagnosis. Based on the data from the most recent follow up and additional telephone interviews, we ...

ea0090rc10.3 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study

Jensterle Mojca , Ferjan Simona , Goricar Katja , Janez Andrej

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...

ea0063gp247 | Disturbances of Reproduction | ECE2019

The efficacy of long-term metformin treatment in overweight and obese women with PCOS: A 10-year database study

Jensterle Mojca , Aleksandra Kravos Nika , Goricar Katja , Janez Andrej

Context: Metformin is an established therapy for women with PCOS and pre-diabetes or diabetes when lifestyle modification is insufficient. Metformin should also be considered in women with PCOS with BMI≥25 kg/m2 independently of the presence of metabolic disturbances. However, its long-term efficacy in this subset of patients is inadequately studied.Aim: We analyzed collection data of 10 years for the efficacy of metformin on body mass (...